ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

Zometa Can Reduce Risk Of Skeletal-Related Events

August 26, 2011

“Bring Contracts Under Control, Save $100,00 A Year,” Samuels Tells NCI

November 2, 1979

IOM Committee Focuses on Studies Needed To Protect Patients On Omics-Based Trials

November 4, 2011

M. D. Anderson Buys Record System For In-Patient Services From Atlanta Firm.

May 4, 2001

In Brief: CFO Dwain Morris to Leave MD Anderson Cancer Center

May 2, 2014

“The President Has Cancer”: NCI Surgery Chief Breaks The News To Reagans And The World as Chief Spokesman After Surgery

July 19, 1985